Johnson & Johnson releases Phase 3 coronavirus vaccine data

Johnson & Johnson releases Phase 3 coronavirus vaccine data

 

Johnson & Johnson's single-shot Covid-19 vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the company announced last week.   The vaccine was 72% effective against moderate and severe disease in the United States, the company said.   Experts say the Johnson & Johnson vaccine will be useful a useful tool in the pandemic in the United States and around the world.   "If you can prevent severe disease in a high percentage of individuals, that will alleviate so much of the stress and human suffering and death," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.   Johnson & Johnson is expected to apply to the US Food and Drug Administration this week for emergency use authorization.   Want to know why these numbers are so promising? Below, I break down what these numbers mean.